Biopharmaceutical IndustrySanofi's ambitious $1.4 billion acquisition of Kymab was expected to reinforce its portfolio in anticipation of the Dupixent patent cliff. However, another Kymab-developed therapy has failed clinical expectations for atopic dermatitis, renewing concerns over the success of recent M&A moves and raising critical questions about the future of Sanofi's immunology strategy.
Dr. Alex Morgan·Jul 25, 2026
Regulatory & PolicyThe United States has experienced an unprecedented surge in measles cases, topping the record from 2025 and signaling a troubling decline in national vaccination coverage. Public health officials are sounding the alarm, warning that eroding confidence in routine immunizations could set the stage for further outbreaks and setbacks in disease control.
Dr. Alex Morgan·Jul 24, 2026 
Biopharmaceutical IndustryIn a notable move, Novartis has discontinued development of a mid-stage radiopharmaceutical asset following unsatisfactory clinical data. This decision underscores the competitive dynamics of oncology R&D and highlights the shifting investment landscape as the company doubles down on its successful asset, Pluvicto.
Dr. Alex Morgan·Jul 22, 2026 
Regulatory & PolicyA closer examination of the FDA’s 505(b)(2) pathway reveals a regulatory mechanism that can accelerate innovation, reduce costs, and extend product lifecycles for the pharmaceutical industry. Yet, the potential of this approach is often underestimated, prompting experts to call for a renewed strategic focus from both established and emerging biopharma firms.
Dr. Alex Morgan·Jul 21, 2026 
Medical TechnologyThe escalation of artificial intelligence and automated software in healthcare’s prior authorization and reimbursement processes is creating a heavily automated ‘arms race’ between payers and providers. Industry insiders now warn that this competitive automation increases administrative costs and may ultimately complicate patient care—unless genuine data interoperability and collaboration occur.
Dr. Alex Morgan·Jul 18, 2026 
Biopharmaceutical IndustryGSK’s discontinuation of its cough program centered on Camlipixant signifies a cautionary tale about the risks and uncertainties facing large-cap pharmaceutical acquisitions. The outcome provides insight into how strategic bets in biopharma can shift course dramatically in the face of late-stage clinical trial setbacks.
Dr. Alex Morgan·Jul 17, 2026 
Regulatory & PolicyMedicare’s test of AI-powered prior authorization remains ongoing following a GOP-led Senate block of efforts to stop the program. This decision fuels debate over the impact of automated decision-making on access to care, administrative burden, and regulatory oversight.
Dr. Alex Morgan·Jul 16, 2026 
Regulatory & PolicyAs AI technologies proliferate within healthcare institutions, a groundbreaking lawsuit filed by a former Mayo Clinic leader puts the spotlight on the balance between innovation, patient safety, institutional accountability, and the regulatory environment. With artificial intelligence playing an ever-expanding role in decision support and patient care, this case reflects the mounting tension between front-line experts and administrative priorities in large health systems.
Dr. Alex Morgan·Jul 13, 2026 
AI in Drug DiscoveryBiopharma’s embrace of artificial intelligence has been enthusiastic, but a new analysis counsels that next-generation AI-enabled drug discovery will remain limited unless companies redesign how their R&D units are organized and operate. This post explores the implications and requirements for transformative change in the industry.
Dr. Alex Morgan·Jul 9, 2026 
Healthcare InvestmentM&A activity picks up pace as Vertex Pharmaceuticals leads the way in large-scale consolidation, with industry observers noting FDA’s continued steady output amid leadership turmoil. Meanwhile, IPOs and venture investment favor established, derisked biotechs; newcomers compete in a risk-averse landscape.
Dr. Alex Morgan·Jul 8, 2026 
Biotech InnovationThe latest funding round positions Celea Therapeutics to directly challenge established IPF therapies with its next-generation candidate. This pivotal trial could have far-reaching implications for patients struggling with progressive lung disease, the biotech landscape, and future standards of care in pulmonary medicine.
Dr. Alex Morgan·Jul 5, 2026 
AI in Drug DiscoveryAs static chatbots reach their limits, the emergence of agentic AI promises to fundamentally change how healthcare tasks are managed for patients and providers alike. This article examines the real-world opportunities and dilemmas that come with entrusting sensitive healthcare functions to autonomous AI agents.
Dr. Alex Morgan·Jul 4, 2026 